Brief: Kempharm Announces Strategic Acquisition Of Arimoclomol From Orphazyme

Strategic Partners A/S

16/05/2022 01:03

May 15 (Reuters) - KemPharm Inc  KMPH.O :
    * ANNOUNCES STRATEGIC ACQUISITION OF ARIMOCLOMOL FROM
ORPHAZYME,
EXPANDING ITS RARE CNS DISEASES PIPELINE
    * PLANS TO REFILE NEW DRUG APPLICATION (NDA) FOR ARIMOCLOMOL
IN
NPC WITH U.S. FOOD AND DRUG ADMINISTRATION (FDA) AS EARLY AS Q1
OF 2023
    * FOR YEAR ENDING DECE 31, 2022, EAP IS EXPECTED TO GENERATE
AT
LEAST USD $12 MILLION IN REVENUE BASED UPON ENROLLMENT IN FRANCE
AS OF MARCH 2022

Source text for Eikon:  ID:nGNX24nRLZ 
Further company coverage:  KMPH.O 

 ((Reuters.Briefs@thomsonreuters.com;))